RVTY ▼ -1.2% - Revvity, Inc. $RVTY - Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery Revvity announced it will acquire Human Cell Design, a developer of advanced cell models for metabolic disease research, to expand its capabilities in drug discovery. The stock declined 1.2% following the announcement, suggesting investors may have concerns about the acquisition's cost, integration challenges, or near-term financial impact despite the strategic rationale of bolstering its cell model offerings. 09-SEP-2026 06:04 AM ET